Paper Details

  1. Home
  2. Paper Details

Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).

Author: BenhadjiKarim A, FakihMarwan G, GeorgeBen, GhidiniMichele, MakrisLukas, ShitaraKohei, SundarRaghav, TaiebJulien

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This post hoc exploratory analysis of the TAGS trial assessed the impact of prior therapy type on the efficacy of trifluridine/tipiracil for metastatic gastric/gastroesophageal junction cancer. Trifluridine/tipiracil demonstrated survival benefits versus placebo regardless of prior treatment type, including patients who had received ramucirumab, paclitaxel, or irinotecan. The safety profile was consistent across subgroups.
Paper Details　
Original Abstract of the Article :
BACKGROUND: In the phase III TAGS trial, trifluridine/tipiracil showed survival benefit versus placebo in patients with metastatic gastric/gastroesophageal junction cancer and ≥ 2 prior chemotherapies. This post hoc exploratory analysis assessed the impact of prior therapy type on outcomes. METHODS...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374776/

データ提供：米国国立医学図書館（NLM）

The Impact of Prior Therapies on Trifluridine/Tipiracil Outcomes in Gastric Cancer

The study explores the effectiveness of [trifluridine/tipiracil] in patients with [metastatic gastric/gastroesophageal junction cancer] who have received [≥2 prior chemotherapies]. The researchers conducted a [post hoc exploratory analysis] of data from the [TAGS trial] and found that [trifluridine/tipiracil] was associated with survival benefits compared to [placebo] regardless of [prior treatment type]. The study highlights the potential of [trifluridine/tipiracil] as a valuable therapeutic option for patients with [metastatic gastric/gastroesophageal junction cancer], even after multiple prior therapies.

Navigating Treatment Options for Gastric Cancer

The study provides valuable insights into the potential of [trifluridine/tipiracil] as a [third- or later-line treatment] option for [metastatic gastric/gastroesophageal junction cancer]. The study's finding that [trifluridine/tipiracil] demonstrated survival benefits regardless of [prior treatment type] suggests that it can be a valuable tool in the arsenal of treatments for this challenging disease.

Hope for Gastric Cancer Patients

This research offers a ray of hope for patients with [metastatic gastric/gastroesophageal junction cancer], particularly those who have already received multiple prior therapies. The study's findings underscore the importance of exploring all available treatment options to maximize survival benefits. Just as a desert landscape can be transformed by a refreshing rainstorm, this research brings hope for a better future for patients with [gastric cancer].

Dr.Camel's Conclusion

This research highlights the potential of [trifluridine/tipiracil] as a [third- or later-line treatment] option for [metastatic gastric/gastroesophageal junction cancer]. The study's findings suggest that [trifluridine/tipiracil] can be a valuable tool for extending survival and improving quality of life for patients with this challenging disease. This research, like a desert traveler discovering a hidden oasis, offers a renewed sense of hope for those who have been navigating the difficult terrain of [gastric cancer].

Date :
  1. Date Completed 2023-08-01
  2. Date Revised 2023-08-01
Further Info :

Pubmed ID

37213030

DOI: Digital Object Identifier

PMC10374776

Related Literature

Article Analysis
・Effects of trifluridine and tipiracil
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.